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With a better understanding of the etiology of breast cancer, molecularly targeted drugs
have been developed and are being testing for the treatment and prevention of breast
cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated path-
ways include the selective ER modulators (tamoxifen, raloxifene, and lasofoxifene) and
aromatase inhibitors (AIs) (anastrozole, letrozole, and exemestane) have been tested in
preclinical and clinical studies. Tamoxifen and raloxifene have been shown to reduce the
risk of breast cancer and promising results of AIs in breast cancer trials, suggest that
AIs might be even more effective in the prevention of ER-positive breast cancer. However,
these agents only prevent ER-positive breast cancer.Therefore, current research is focused
on identifying preventive therapies for other forms of breast cancer such as human epi-
dermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC,
breast cancer that does express ER, progesterone receptor, or HER2). HER2-positive breast
cancers are currently treated with anti-HER2 therapies including trastuzumab and lapatinib,
and preclinical and clinical studies are now being conducted to test these drugs for the pre-
vention of HER2-positive breast cancers. Several promising agents currently being tested
in cancer prevention trials for the prevention ofTNBC include poly(ADP-ribose) polymerase
inhibitors, vitamin D, and rexinoids, both of which activate nuclear hormone receptors (the
vitamin D and retinoid X receptors). This review discusses currently used breast cancer
preventive drugs, and describes the progress of research striving to identify and develop
more effective preventive agents for all forms of breast cancer.
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INTRODUCTION
Breast cancer is the most common cancer among women, with
an estimated 232,340 new cases, in 2013 in the U.S. alone (1).
This represents close to 30% of all estimated new cancer cases in
women, and after a decline in the incidence rate, largely due to the
reduction in the use of hormone replacement therapy (2, 3), the
incidence rate has been stable for the past decade (1). Although
there has been a steady decrease in breast cancer mortality since
the early 90s (1), due largely to improvements in the early detec-
tion and treatment of breast tumors (4), in the U.S. approximately
40,000 women will die of breast cancer this year (1). Despite these
positive reductions in mortality, preventing breast cancer prior to
its development remains the most effective way to reduce mortality
resulting from this disease. Recent clinical trials have now demon-
strated that effective prevention is possible for some forms of breast
cancer, and rapid advances being made during this genomic era are
providing further understanding of breast cancer subtypes, laying
the foundation for the development of preventive therapies for all
forms of breast cancer.
Genomic profiling of breast cancer using expression arrays has
proven useful for the elucidating different molecular forms of
breast cancer. The analysis of gene expression patterns by Perou et
al. (5), led to the discovery and identification of four distinct mole-
cular subtypes of breast cancer with RNA expression profiles divid-
ing the tumors into at least four subgroups (5). These subgroups
are characterized by variations in overexpression, with the luminal
subgroup highly expressing genes normally associated with breast
luminal cells, the second subgroup expressing genes typically active
in breast basal epithelial cells (basal-like subgroup), and the third
subgroup overexpressing human epidermal growth factor recep-
tor 2 (HER2 subgroup), which is associated with a unique set of
genes. The fourth tumor subgroup consists of tumors that cluster
with normal breast samples, and are classified as normal-like breast
tumors. Follow-up analysis of a tumor set approximately twice the
size as the original, demonstrated distinct differences in survival
and treatment response between different molecular subtypes (6)
(see Table 1). Luminal A tumors were associated with the longest
overall survival, while HER2 and basal-like tumors were associ-
ated with decreased survival. Similar results were observed with
time to recurrence (6). It is important to note that these tumors
were obtained prior to the widespread use of anti-HER2 therapies,
thus explaining the poor survival of the HER2 group. These find-
ings have since been confirmed in a population-based study (7).
However, the drivers for decreased overall and disease-free survival
in women with basal-like tumors remain unclear. In 2007, Perou
et al. extended their initial findings by identifying yet another
molecular subtype, the claudin-low tumors, which underexpress
genes involved in tight-junctions and cell–cell adhesion, includ-
ing several Claudin genes and E-cadherin and high expression of
endothelial markers (8). From a clinical perspective, these claudin-
low tumors are associated with a poor prognosis (9). The basal and
claudin-low molecular subtypes significantly overlap the clinical
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Table 1 | Molecular subtypes of breast cancer.
Molecular subtype Gene expression Survival
Perou et al. (5), Sorlie et al. (6)
Luminal High expression of genes normally expressed in breast luminal cells Longest overall survival
Basal-like High expression of genes normally expressed in breast basal cells Shortest overall survival
HER2 Overexpression of human epidermal growth factor receptor 2 (HER2)
and a unique gene set
Decreased overall survival
Claudin-low High expression of genes involved in tight-junctions and cell-to-cell
adhesion, including E-cadherin and several claudin genes
Decreased overall survival
Lehmann et al. (10)
Immunomodulatory Overexpression of cytokine signaling and antigen processing
pathway genes
Reduced relapse-free survival compared to
mesenchymal stem-like
Mesenchymal Overexpression of cell motility and differentiation genes Reduced relapse-free survival compared to
basal-like 1, basal-like 2, mesenchymal
stem-like, and immunomodulatory
Mesenchymal stem-like Overexpression of cell motility and differentiation genes Longest relapse-free survival
Luminal androgen receptor Activation of the hormone signaling pathways Shortest relapse-free survival
Basal-like 1 Overexpression of cell cycle and cell division genes Intermediate relapse-free survival
Basal-like 2 Enhancement of the growth factor signaling pathways Intermediate relapse-free survival
triple-negative breast cancers (TNBCs), which have low levels of
ER, PR, and HER2 proteins. TNBCs exhibit a high level of mol-
ecular heterogeneity, are highly aggressive, and have proven chal-
lenging for the development of targeted therapeutic treatments,
and for the development of effective preventive strategies.
To further define the TNBC subtypes, Lehmann et al. ana-
lyzed the gene expression profiles of 21 breast cancer data sets,
which included almost 600 TNBCs and identified six distinct
subtypes: (1) immunomodulatory, (2) mesenchymal, (3) mes-
enchymal stem-like, (4) luminal androgen receptor, (5) basal-like
1, and (6) basal-like 2 (10). Stratification of breast cancer cell
lines according to the same gene expression profiles, demon-
strated that these six TNBC subtypes are uniquely sensitive to
different drugs. Furthermore survival varies across each of these
subtypes, with mesenchymal stem-like and luminal androgen
receptor associated with the longest and shortest relapse-free sur-
vival, respectively (see Table 1). Overexpression of immune cell
processing genes (e.g., cytokine signaling and antigen processing
pathway genes) characterizes the immunomodulatory subtype,
forming a rationale for developing preventive agents targeting
the immune system, cytokines, and immune signal transduction
pathways. The mesenchymal and mesenchymal stem-like sub-
types exhibit enrichment for pathways involved with cell motility
and cell differentiation, providing the foundation for studies of
drugs targeting pathways regulating cell migration. The lumi-
nal androgen receptor subtype is ER-negative. However, estro-
gen and androgen hormone signaling pathways are activated in
these tumors, supporting the use of anti-androgens and pos-
sibly anti-estrogens, for the treatment and prevention of these
tumors. Upregulation of the cell cycle and cell division path-
ways defines basal-like subtype 1, suggesting the potential efficacy
of anti-mitotic and DNA-damaging drugs, as well as poly(ADP-
ribose) polymerase (PARP) inhibitors to treat and possibly prevent
tumors of this type. The final subtype, basal-like subtype 2 is
associated with enhancement of the growth factor signaling path-
ways, suggesting strategies targeting the epidermal growth factor
receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R),
met proto-oncogene (MET), nerve growth factor (NGF), and
Wnt/beta-catenin pathways, along with genes involved in gluco-
neogenesis and glycolysis, may be useful for the treatment and
prevention of this group of tumors. The major challenge will be
to determine the minimal number of drugs to combine to prevent
all of these forms of cancer, and to select drugs that will be both
effective and safe.
PREVENTION OF ER-POSITIVE (LUMINAL) BREAST CANCERS
SELECTIVE ESTROGEN RECEPTOR MODULATORS
Estrogen and the estrogen receptors (ERs) are key regulators in
the progression of breast cancer, as well as other hormonally stim-
ulated cancers. For this reason, drugs targeting ER, known as
selective estrogen receptor modulators (SERMs), were developed
and have been used for decades to suppress the estrogen signaling
pathway in women with breast cancer (Figure 1). Tamoxifen, the
first SERM to be approved for the treatment of metastatic breast
cancer, has been shown to have antagonistic effects in breast, while
acting as an agonist in other tissues. Tamoxifen is routinely used to
treat all stages of breast cancer. Adjuvant breast cancer trials have
demonstrated that tamoxifen reduces both breast cancer recur-
rence and contra-lateral breast cancer by approximately 40–50%
in women with early breast cancer (11). The positive results from
these trials opened the door to test the preventive effects of tamox-
ifen in women without breast cancer. Four major Phase III breast
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FIGURE 1 | Oncogenic pathways as molecular targets for the prevention of breast cancer. Solid lines represent drugs and targets currently being used in
the prevention of breast cancer; dotted lines represents drugs currently in development.
cancer prevention trials have now demonstrated the efficacy of
tamoxifen in women at high risk for developing breast cancer.
Across these studies, tamoxifen reduced overall breast cancer inci-
dence between 16 and 49% (12), and ER-positive breast cancer
incidence between 31 and 69% (see Table 2).
The first of the breast cancer prevention trials to be conducted
was the Royal Marsden Tamoxifen Breast Cancer Prevention Trial,
which was conducted from 1986 to 1996 (13, 28, 29). This trial
found a non-significant 39% reduction during the 8-year treat-
ment period, but was significantly lower in the post-treatment
period in ER-positive breast cancer incidence (13). There was no
reduction in ER-negative breast cancer incidence. The second, and
largest, clinical prevention trial testing tamoxifen was the National
Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Can-
cer Prevention Trial (BCPT) P-1 (14, 30). This trial recruited
over 13,000 women at increased risk for invasive breast cancer
to study the effects of 5 years of tamoxifen treatment in pre- and
post-menopausal women. The results showed a significant 49%
reduction in overall incidence of invasive breast cancer, and a 69%
reduction in ER-positive breast cancers. There was not only reduc-
tion in the incidence of breast cancer in higher risk women without
breast cancer, but an impressive reduction in women with a his-
tory of lobular carcinoma in situ or atypical hyperplasia of 56
and 86% respectively. These results formed the foundation for
FDA approval of tamoxifen for the prevention of breast cancer in
high-risk pre- and post-menopausal women in 1998. The results
of the NSABP P-1 trial also identified tamoxifen-associated toxic-
ities, including increased risk of thromboembolisms, endometrial
cancer, hot flushes, vaginal symptoms, and cataracts (14, 30).
The Italian breast cancer prevention trial, the third to test
the preventive effects of tamoxifen in breast cancer, included
5,408 women at normal risk for breast cancer. In order to avoid
the increased incidence of endometrial cancers associated with
tamoxifen use, only women who had previously undergone a hys-
terectomy were enrolled (15, 31). Although many of the women
enrolled in this study were on hormone replacement therapy,
which has since been shown to increase risk of breast cancer,
a reduction of 20% in invasive breast cancer incidence was still
observed.
The fourth breast cancer prevention clinical trial testing tamox-
ifen for the prevention of breast cancer was the International
Breast Cancer Intervention Study I (IBIS-I), in which women at
high-risk were treated with tamoxifen for 5 years (32). Tamox-
ifen reduced the occurrence of ER-positive breast cancers by 48%,
and the long-term follow-up of this trial suggested a persistent
benefit after stopping treatment for at least 10 years, demonstrat-
ing a 31% reduction in invasive ER-positive breast cancer after
long-term follow-up (16). Another encouraging finding identified
during the follow-up was a reduction in the negative side effects
of tamoxifen after stopping the drug.
While each of the four trials demonstrated effective prevention
of many ER-positive breast cancers with tamoxifen treatment, no
reduction in the progression of ER-negative tumors was observed
in any of these trials. All four trials reported long-term side-effects
associated with tamoxifen treatment, including hot-flashes, night
sweats, and vaginal symptoms, as well as more severe side effects,
including increased risk of endometrial cancer and thromboem-
bolism. Due to these tamoxifen-related side effects, focus shifted
toward the development of less toxic second generation SERMs.
The first trial investigating a SERM other than tamoxifen for
breast cancer prevention was the Multiple Outcomes of Ralox-
ifene Evaluation (MORE) trial that tested the effect of raloxifene
on bone fractures in postmenopausal women with osteoporosis,
and also tested its effect on several other endpoints, including
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breast cancer (see Table 2). The trial demonstrated a 76% reduc-
tion in invasive breast cancer incidence and a 90% reduction of
ER-positive breast cancer incidence after 3 years of treatment (17).
These impressive results led to the development of two additional
clinical cancer prevention trials testing the effectiveness of ralox-
ifene in the prevention of invasive breast cancer. These trials, the
Continued Outcomes of Raloxifene Evaluation (CORE) trial and
the Raloxifene Use for the Heart (RUTH) trials, were conducted
concurrently by two different groups. The CORE trial was an
extension of the MORE trial, and confirmed that long-term treat-
ment with raloxifene reduces the incidence rate of invasive ER-
positive breast cancers, but has no preventive effect on ER-negative
Table 2 | Selective estrogen receptor modulator, AI, and HER2 breast cancer prevention clinical trials.
Trial Study design Patient characteristics Results
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)
Tamoxifen
Royal Marsden trial (13) Tamoxifen vs. placebo 2,494 High-risk women Reductions in all BC (16%) and
ER-positive BC (39%)
NSABP-(BCPT)-P-1 (14) Tamoxifen vs. placebo 13,388 High-risk women 49% Reduction in all BC
Italian trial (15) Tamoxifen vs. placebo 5,408 Normal-risk women
with hysterectomy
Reductions in BC (16%) and
ER-positive BC (69%)
IBIS-I (16) Tamoxifen vs. placebo 7,154 High-risk women Reductions in all BC (27%) and
ER-positive BC (31%)
Raloxifene
MORE (17) Raloxifene (60 or 120 mg) vs. placebo 7,705 Normal-risk women with
osteoporosis
Reductions in all BC (65%) and
ER-positive BC (90%)
CORE (18) Extension of MORE trial 5,213 Women from MORE trial Reductions in all BC (50%) and
ER-positive BC (66%)
RUTH (19) Raloxifene vs. placebo 10,101 Postmenopausal women with
coronary heart disease
Reductions in all BC (44%) and
ER-positive BC (55%)
Tamoxifen vs. raloxifene
STAR (20) Tamoxifen vs. raloxifene 19,747 High-risk women 5-years: raloxifene and tamoxifen
equally effective for preventing
progression to breast cancer
81 months: raloxifene is 75% effective
as tamoxifen
Lasofoxifene
PEARL (21) Lasofoxifene vs. placebo 8,556 Women with osteoporosis Reductions in all BC (79%) and
ER-positive BC (81%)
AROMATASE INHIBITORS (AIs)
IBIS-II – DCIS (12, 22) Tamoxifen vs. anastrozole 4,000 Women with DCIS Anticipated in 2 years
NSABP B-35 Tamoxifen vs. anastrozole 3,104 Women with ER-positive DCIS Anticipated in 2 years
NCIC-MAP.3 (23) Exemestane vs. placebo 4,560 Postmenopausal high-risk women Reductions in all BC (65%) and
ER-positive BC (75%)
IBIS-II (24) Anastrozole vs. placebo 6,000 Postmenopausal high-risk women Anticipated in 3 years
HER2 INHIBITORS
Trastuzumab
Kuerer et al. (25) Trastuzumab vs. placebo 24 Women with HER2-positive DCIS No histologic evidence of response;
increased ADCC in 100% of patients
Decensi et al. (26) Lapatinib vs. placebo 60 Women with early HER2-positive
cancer
Reduction in proliferation in early
cancer and pre-cancer
Brown et al. (27) Lapatinib vs. placebo 60 Women with EGFR or HER2-positive
DCIS
Ongoing: endpoint alteration in
proliferation
ADCC, antibody-dependent cellular cytotoxicity; BC, breast cancer; CORE, continued outcomes of raloxifene evaluation; DCIS, ductal carcinoma in situ; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemical staining; IBIS, Italian, Italian randomized tamoxifen prevention trial; MORE,
multiple outcomes of raloxifene evaluation; NCIC CTGMAP.3, or NCIC-MAP.3, the National Institute of Canada ClinicalTrials GroupMammary Prevention.3 trial; NSABP
B-35, National Surgical Adjuvant Breast and Bowel Project B-35; NSABP-P-1, NSABP Breast Cancer PreventionTrial (BCPT) P-1; NSABP-P2, NSABP Study ofTamoxifen
and Raloxifene (STAR) P2; PEARL, postmenopausal evaluation and risk reduction with lasofoxifene trial; RUTH, raloxifene use for the heart trial; Royal Marsden, Royal
Marsden tamoxifen prevention trial.
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breast cancers (18). The long-term follow-up of women on either
4 or 8 years of raloxifene treatment showed decreases of 31 and
59% in invasive breast cancer, respectively (33). This clearly indi-
cates that extended treatment with raloxifene prevents ER-positive
breast cancer. The RUTH trial, on the other hand, was specifically
designed to evaluate the effects of 5 years of raloxifene treatment
on the incidence rates of coronary events and invasive breast can-
cer. A 44% reduction of overall invasive breast cancer incidence
and a 55% of ER-positive breast cancer incidence was observed.
These results were similar to the MORE and CORE trails (19, 34).
Another important observation was that no statistically significant
increase in incidence of endometrial cancer was observed in any
of the three raloxifene trials.
Based on the collective results of the tamoxifen and ralox-
ifene clinical prevention trials, the NSABP Study of Tamoxifen and
Raloxifene (STAR) trial was developed to compare the effective-
ness of 5 years of treatment with these two drugs in decreasing risk
of breast cancer in high-risk postmenopausal women (see Table 2)
(20). The initial results showed that tamoxifen and raloxifene were
equally effective in their ability to decrease risk of breast cancer,
with both reducing agents risk by approximately 50% (20). How-
ever, the study also identified differences in toxicities between the
two arms, with patients receiving raloxifene reporting fewer side-
effects and having fewer cases of blood clots and uterine cancers.
The long-term follow-up of the STAR trial revealed that ralox-
ifene was less effective for the prevention of invasive breast cancer,
retaining only 76% of its long-term preventive effects compared
to tamoxifen (35). Thus, the cancer preventive effect of ralox-
ifene is not as persistent as that of tamoxifen. However, a major
potential advantage of raloxifene is that it has fewer side-effects
(decreased incidence of uterine cancers and thromboembolisms
in raloxifene-treated women). Therefore, postmenopausal women
and their doctors have a choice: they can choose the most effec-
tive preventive SERM, tamoxifen, and accept its toxicities, or they
can choose the slightly less effective, but more tolerable SERM,
raloxifene. In 2007, based upon the early findings in the Star trial,
raloxifene received FDA approval for preventive treatment of post-
menopausal women with osteoporosis or at high risk for invasive
breast cancer.
More recently, the third generation SERM lasofoxifene has
been tested as a breast cancer preventive drug (see Table 2). A
Phase III clinical trial demonstrated the preventive efficacy of
lasofoxifene in postmenopausal women with osteoporosis. The
Postmenopausal Evaluation and Risk Reduction with Lasofoxifene
(PEARL) trial, in which women were treated with lasofoxifene
for 5 years, reported an 81% reduction in ER-positive breast can-
cer incidence. In addition, lasofoxifene treatment was associated
with decreased toxicity compared to both tamoxifen and raloxifene
(21). Despite this extremely high level of efficacy, lasofoxifene has
not yet been FDA-approved for a breast cancer prevention indi-
cation. Thus, tamoxifen and raloxifene currently remain the only
SERMs approved by the FDA for the prevention of breast cancer.
AROMATASE INHIBITORS
Aromatase inhibitors (AIs) represent an alternative strategy to
prevent ER-dependent breast cancers. AIs such as letrozole,
anastrozole, and exemestane, block the biosynthesis of estrogen
from androgens through the inhibition of the aromatase enzyme,
resulting in drastic reductions in the circulating estrogen levels
of serum, tissue, and tumor cells (36) (Figure 1). The aromatase
enzyme is present in fat, stromal, and muscle cells, but is also
expressed in breast tumors (37). In adjuvant breast cancer trials,
AIs have proven to be an effective treatment strategy in pre-
menopausal women with ER-positive breast cancer, even more
effective than tamoxifen. As with tamoxifen, the cancer preventive
potential of AIs was suggested by results of early breast cancer trials
which showed a reduction in contralateral breast incidence. Sev-
eral clinical trials demonstrated increased time to recurrence and
improved efficacy in the prevention of a second primary breast
cancers following treatment with AIs as compared to tamoxifen
(23, 38). In addition, AI treatment is not associated with increased
thromboembolic events and uterine cancers, although increased
risk of bone fractures has also been observed (39). The National
Cancer Institute of Canada Clinical Trials Group MA.17 (NCIC
CTG MA.17) trial demonstrated that switching to the AI letro-
zole after 5 years of tamoxifen reduced the risk of contra-lateral
breast cancer in patients diagnosed with ER-positive breast cancer
(40) The largest of the trials investigating the efficacy of an AI as an
adjuvant therapy was the Arimidex, Tamoxifen Alone or in Combi-
nation (ATAC) trial. The long-term follow-up of this trial demon-
strated that AI therapy with anastrozole produced more persistent
and effective protection against contralateral ER-positive breast
cancer incidence than tamoxifen (41).
Two cancer prevention trials are currently ongoing in women
with ductal carcinoma in situ (DCIS), comparing the AI anastro-
zole and tamoxifen, the NSABP B-35 and IBIS-II (DCIS) trials (see
Table 2). Results from these trials are expected to be released in
1–2 years. In both of these trials women with ER-positive DCIS
are being treated with the AI anastrozole or tamoxifen for 5 years.
Both the NSABP B-35 and IBIS-II (DCIS) trials have completed
accrual and results are anticipated in the near future. The primary
endpoint of both trials is the incidence of invasive breast can-
cer, with important secondary endpoints including incidence of
contralateral breast cancer and toxicity.
Based on the results of the adjuvant AI therapy trials, sev-
eral large clinical cancer prevention trials were developed to test
the effectiveness of AIs in preventing breast cancer in high-risk
women without breast cancer. Two Phase III prevention trials are
currently being conducted testing AIs in postmenopausal women,
the MAP.3 trial and the IBIS-II prevention trials (see Table 2)
(12, 22, 42). Results of the MAP.3 trial comparing the AI exemes-
tane with placebo in high-risk women without breast cancer have
been reported and show a 74% reduction in invasive ER-positive
breast cancer incidence, associated with no increased in incidence
of osteoporosis or endometrial cancers, following treatment with
the AI exemestane. However, this trial had a short follow-up
period when these results were reported. More significant toxic
effects may be observed with a longer follow-up. For these rea-
sons, exemestane is not yet FDA-approved for the prevention of
breast cancer.
The early results of the MAP.3 trial suggest AIs will be highly
effective for the prevention of ER-positive breast cancer. However,
neither SERMs nor AIs prevent ER-negative breast cancer. These
observations indicate that to prevent ER-negative breast cancers it
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will be necessary to target molecules critical for the growth and
progression of ER-negative tumors.
HER2 INHIBITORS
Human epidermal growth factor receptor 2 is a member of the
EGFR family of receptor tyrosine kinases. Upon phosphoryla-
tion of MAPK, EGFR signaling regulates the transportation of
mitogenic signals across the cell membrane via a signaling cas-
cade. Once intracellular, these signals induce proliferation and
inhibit cell death; thus, misregulation of this pathway results in
uncontrolled growth and inhibition of apoptosis. Overexpression
of growth factor receptors has been identified in many different
cancers, with HER2 overexpression present in 20–25% of breast
cancers (43, 44). By targeting HER2 through different molecular
mechanisms, EGFR inhibitors, and particularly HER2 inhibitors
(including trastuzumab and the dual EGFR/HER2 inhibitor lapa-
tinib), inhibit tumor growth, and induce apoptosis. The human-
ized HER2 antibody trastuzumab, targets the extracellular domain
of HER2, while lapatinib inhibits the kinase activity of HER2 and
EGFR (Figure 1). Both trastuzumab (44) and lapatinib (43) have
been shown to be effective in the adjuvant setting for women
with HER2-positive breast cancer. Research is now focused on
determining whether HER2-positive breast cancers can be pre-
vented by treating patients earlier at the stage of non-invasive
breast cancer. Our group has shown that HER2-transgenic mice
treated with the HER2/EGFR dual kinase inhibitor lapatinib (45)
or the EGFR inhibitor gefitinib (46) have delayed development
of HER2-positive mammary tumors. These studies demonstrated
that treatment with the lapatinib also inhibits the development of
mammary gland pre-malignant lesions in these mice (45).
Due to these positive adjuvant clinical trial and preclinical study
results demonstrating delay of HER2-positive tumors following
treatment with HER2 inhibitors, clinical cancer prevention trials
have been developed to test trastuzumab or lapatinib in women
with HER2-positive DCIS lesions. A Phase II trial testing a single
pre-operative dose of trastuzumab in women with HER2-positive
DCIS demonstrated an immunologic response that was not asso-
ciated with either a pathologic or proliferation-related response
(see Table 2) (25). The ongoing NSABP B-43 trial is testing the
effects of radiation alone or in combination with two doses of
trastuzumab (after surgical excision of the DCIS) on ipsilateral
incidence of recurrent DCIS, invasive breast cancer or skin can-
cer. The results of a Phase II trial recently testing lapatinib for
the treatment of HER2-positive breast cancer (early-stage invasive
breast cancer and DCIS) showed that lapatinib (at 1,500 mg/day)
decreased breast cancer cell proliferation in ER-negative tumors
and in DCIS and ductal hyperplasia lesions (26). Another similar
trial in women with HER2-positive or EGFR-positive DCIS breast
cancer testing the effect of a lower dose of lapatinib (1,000 mg/day)
is currently ongoing.
To date, the results from the preclinical and early clinical cancer
prevention trials studying the effectiveness of EGFR inhibitors as
viable preventive strategies for women with HER2-positive breast
cancer are very promising. However, breast cancers that do not
express ER, PR, or HER2, will not benefit from these targeted
treatments.
In addition to HER2 inhibitors, HER2 peptide vaccines are
being studied as therapeutic agents to induce immune responses
to HER2-positive breast cancers. Such HER2 vaccines may in the
future be most useful for the prevention of HER2-positive breast
cancers. HER2 antibodies have been shown to be present in pre-
diagnostic breast cancer sera (47). This observation supports the
development of anti-HER2 vaccine approaches using HER2 pep-
tides as immunogens. Responses to these HER2 peptide vaccines
are restricted to specific major histocompatibility complex (MHC)
classes: Class I (E75, GP2) and II (AE37) peptides simulate CD8-
and CD4-positive T cells, respectively, and have been shown to
induce an antitumor response (48). Results from Phase I and II
clinical trials using these HER2 peptide vaccines have demon-
strated significant immunologic ex vivo and in vivo responses (49,
50), and improved disease-free survival (particularly in patients
with low-HER2 expression) persisting over time (51). In addi-
tion, all of these studies have shown that anti-HER2 vaccination
has minimal toxicity and is easily tolerated by women with prior
breast cancer. The first Phase III clinical trial investigating the
efficacy of an anti-HER2 vaccine (E37) given as adjuvant ther-
apy to women with early-stage node-positive breast cancer (the
Prevention of Recurrence in Early-Stage, Node-Positive Breast
Cancer with Low to Intermediate HER2 Expression with Neu-
Vax Treatment, or PRESENT, trial) is currently ongoing. Future
studies will focus on testing whether these peptides will be use-
ful in high-risk women for the prevention of HER2-positive
breast cancer.
DEVELOPMENT OF PREVENTIVE AGENTS FOR
TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancers represent 15–20% of all breast can-
cers, and are defined by a lack of ER, PR, and HER2 expression,
resulting in limited treatment options. TNBCs are more aggres-
sive, affect younger women, and are higher in incidence among
women of African descent. In addition, these breast cancers have
demonstrated both a higher rate of recurrence and a worse clinical
outcome as compared to the other subtypes of breast cancer. Due
to the lack of well-defined clinical targets, standard chemotherapy
is currently the only treatment option for women with TNBC, and
there are no available preventive drugs.
Recently, six distinct TNBC subgroups were identified through
RNA expression profiling analyses, as mentioned in the introduc-
tion (10). Other studies have similarly identified a set of kinase
gene expression profiles that divide ER-negative breast cancers
into four distinct subtypes, including the cell cycle regulatory, S6
kinase, immunomodulatory, and MAPK clusters (52). In addi-
tion, survival analyses have shown that the subtype driven by the
S6 kinase pathway carries the worst prognosis of the four ER-
negative breast cancer subtypes, and emphasizes the importance
of identifying druggable targets specific for each subtype of breast
cancer.
RETINOIDS
Retinoids are particularly promising drugs for the prevention of
TNBC. These molecules, which are derivatives of vitamin A, bind
retinoic acid receptors (RARs), and affect transcription factors
that regulate gene expression to control development, differentia-
tion, and homeostasis (53) (Figure 1). Studies by our group and
others have demonstrated that retinoids are effective agents for the
prevention of ER-negative breast cancer in animal models (54–58).
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Early preclinical studies in rats indicated a correlation between
vitamin A blood levels and changes in the epithelial tissue from
a stratified keratinizing to a normal epithelium in several organs,
which could be reversed back to stratified keratinized epithelium
by restoring normal vitamin A (59). Further analysis in animals
has since established the ability of retinoids to prevent cancer
(60), demonstrating retinoid-mediated prevention of mammary
carcinogenesis in rats after chemical carcinogen exposure, and in
ER-negative mouse models (54).
A chemoprevention trial focused on the prevention of second
primary tumors of the head and neck was one of the first clinical
trials to demonstrate the effectiveness of retinoids for the preven-
tion of cancer in humans (61). The retinoid 13-cis-retinoic acid
was shown to reduce the incidence of second primary tumors;
however, it has not been used clinically for prevention because
of its toxicity. Similar toxicity has been observed with another
retinoid, 9-cis-retinoic acid (62, 63). Treatment with the synthetic
retinoid fenretinide (4HPR) for 5 years in a Phase III clinical trial
in women with previous early stage breast cancer demonstrated
no overall breast cancer preventive effect, but suggested a benefi-
cial effect in premenopausal women (64). Longer follow-up after
15 years confirmed no overall breast cancer preventive effect, but
showed a statistically significant 38% reduction in second pri-
mary breast cancers in premenopausal women (65). Fenretinide
treatment was also associated with reduced incidence of ovarian
cancer in women taking fenretinide; however, this protective effect
was not apparent after stopping treatment (66).
Other synthetic retinoids, known as rexinoids, have been devel-
oped, which specifically bind the retinoid X receptor (RXR). These
RXR ligands retain the cancer preventive activity of retinoids, but
have much less toxicity. Extensive testing of rexinoids, includ-
ing bexarotene and the more RXR-selective drug LG100268, has
demonstrated a preventive effect with reduced toxicity compared
to retinoids in animal models [e.g., the MMTV-ErbB2 transgenic
and C3(1)-SV40 T-antigen models] (55, 56). More recently, it has
been shown that the combined treatment with rexinoids and anti-
estrogen SERMs is more effective in preventing mammary tumors
than treatment with either agent alone (67, 68).
The positive preclinical rexinoid results supported the devel-
opment of a Phase II clinical trial testing the effect of 4 weeks
of bexarotene treatment in women at high-risk for breast cancer.
Biomarker analysis from this study demonstrated that bexarotene
treatment caused a non-significant reduction in the proliferation
marker Ki67, and a significant reduction of Cyclin D1 expression
in postmenopausal women (27). However, bexarotene was asso-
ciated with toxicities (skin rash and hypertriglyceridemia), which
may limit its clinical use. The rexinoid LG100268 is even more
effective in the prevention of mammary tumors than bexarotene
and has significantly less toxicity, thus LG100268 is a promising
candidate for ER-negative breast cancer prevention in the future
(see Table 3).
COX-2 INHIBITORS
Some of the most promising cancer preventive drugs are
the non-steroidal anti-inflammatory drugs, which specifically
inhibit one or both of the cyclooxygenase (COX)-1 and COX-2
enzymes (Figure 1). While COX-1 is present in most tissues and
overexpressed in a variety of cancers, COX-2 expression is induced
by mitogenic signals and is primarily localized at sites of inflam-
mation (77). A polyp prevention study conducted by Steinbach
et al. showed that patients with familial adenomatous polyposis
(FAP) treated with the COX-2 inhibitor celecoxib exhibited a sig-
nificant regression of colorectal adenomas (78). These results led
to FDA approval of celecoxib for the reduction of colonic polyps in
patients with FAP. Unfortunately, although COX-2 inhibitors have
proven effective drugs to prevent colonic polyp formation, sev-
eral large polyp prevention studies identified rare but potentially
severe cardiovascular toxicities associated with COX-2 inhibitors.
These Phase III trials included the Adenomatous Polyp Preven-
tion on Vioxx (APPROVe) trial (79), which studied the COX-2
inhibitor rofecoxib, and the Prevention of Colorectal Sporadic
Adenomatous Polyps (PreSAP) (80) and Adenoma Prevention
with Celecoxib (APC) (81) trials, which both studied the COX-2
inhibitor celecoxib.
The COX-2 inhibitor celecoxib has also been the focus of stud-
ies investigating its effectiveness in the prevention of ER-negative
breast cancer. Celecoxib has been shown to significantly delay the
onset of tumor formation in MMTV-erbB2 transgenic mice, which
develop primarily ER-negative tumors (82). This observation is
particularly relevant for the prevention of both ER-negative and
TNBCs.
Following these positive preclinical results, several early phase
breast cancer prevention clinical trials testing COX-2 inhibitors
have been conducted (83, 84). Unfortunately, due to the increased
risk of heart attacks reported in the polyp prevention trials, the
FDA halted ongoing COX-2 trials, including several Phase II breast
cancer prevention studies. However, since COX-2 has been shown
to play an important role in multiple cancer types and COX-2 inhi-
bition is effective in preventing ER-negative mammary tumors in
mice, it is likely that research will continue to focus on the devel-
opment of safer and more effective agents targeting the COX-2
pathway.
METFORMIN
Metformin is the most frequently used drug for the treatment of
type-2 diabetes, and has recently been investigated as a cancer pre-
vention drug. A meta-analysis of epidemiologic studies recently
confirmed an association between diabetes and increased risk of
breast cancer (most apparent in postmenopausal patients) (85).
Metformin reduces glucose levels, resulting in the reduction of
insulin levels (86), and treatment with metformin has been shown
to result in the inhibition of breast cancer cell growth in vitro (87).
Therefore, it is possible that decreased insulin levels may reduce the
activation of pathways involved with cell growth, thereby reduc-
ing tumorigenesis. Metformin has also been shown to activate
AMP-activated protein kinase (AMPK) (Figure 1), which recent
studies suggest may overcome resistance to HER2 inhibitors (88).
Metformin has also been shown to slow the growth of mammary
tumors in MMTV-erbB2 transgenic mice (see Table 2) (72, 89).
Several early phase breast cancer clinical trials testing the effects
of metformin on breast tissue biomarkers reported reductions in
cell proliferation following treatment with metformin in women
with operable invasive or early-stage breast cancer (see Table 4).
Each of these studies measured proliferation by Ki67 staining in
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Table 3 | Select additional preclinical and clinical studies of novel agents for breast cancer prevention.
Trial/experiment Study design Treatment group characteristics Results/primary endpoint(s)
EGFR INHIBITORS
Chan et al. (69) Gefitinib vs. placebo Transplant of DCIS tissue in
immuno-suppressed mice
56% Reduction in proliferation, measured by Ki67
Lu et al. (46) Gefitinib (low and high
dose) vs. placebo
MMTV-Erb2 mice High dose gefitinib showed a delay in ER-negative
tumor development
Piechocki et al. (70) Gefitinib vs. placebo MMTV-Erb2 mice Reduction in number and size of tumors
Strecker et al. (45) Lapatinib (low and high
dose) vs. placebo
MMTV-Erb2 mice High dose lapatinib showed a delay in ER-negative
tumor development
REXINOID
Li et al. (57) LG100268 (low and
high dose) vs. placebo
MMTV-Erb2 mice Low dose: delay in ER-negative tumor development
High dose: prevented ER-negative tumor
development in 90% of mice
COX-2 INHIBITORS
Fabian et al.
NCT00056082
Celecoxib vs. placebo 110 Premenopausal women at
high-risk for ER-negative BC
Proliferation: Ki67 IHC staining
Arun et al.
N01-CA-9757
Exemestane± celecoxib 44 Pre- and post-menopausal
high-risk women
Proliferation: Ki67 IHC staining
Wong et al.
NCI-04-0044
Exemestane± celecoxib 72 Postmenopausal high-risk women Mammographic breast density
METFORMIN
Anisimov et al. (72) Metformin vs. placebo MMTV-Erb2 mice Delay in ER-negative tumor development
MTOR INHIBITORS
Torres-Arzayus et al. (73) Everolimus vs. placebo AIB Mice Reversion of pre-malignant phenotype
Kim et al. (74) Rapamycin vs. vehicle Benign, pre-malignant, and breast
cancer cell lines
Most effective in benign and pre-malignant cells
Mercier et al. (75) Rapamycin vs. vehicle Cav-1 knockout mice Tumor growth inhibition; decreased stromal content
IGF-R INHIBITORS
Litzenburger et al. (76) BMS-754807 vs.
placebo
MCF10A Growth inhibition in a pre-malignant cell line
transformed by IGF1R
BC, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IHC, immunohistochemical staining.
breast tumors (90–93). The results of clinical trials currently being
conducted, including a number of Phase II trials and one Phase
III trial, are anticipated in the upcoming years. Of these, the Phase
III NCIC-MA.32 trial is of particular interest, and will examine
the effect of metformin on invasive disease-free survival, over-
all survival, and contralateral breast cancer incidence in women
diagnosed with early stage breast cancer. The results reported at
the conclusion of these studies will further define the breast can-
cer preventive activity of metformin, and determine its relevance
as an effective strategy for the prevention of ER-negative breast
cancer.
STATINS
Statins have been used as cholesterol-lowering drugs for over
three decades with great success (Figure 1). Preclinical in vitro
and in vivo studies have demonstrated that statins inhibit pro-
liferation of breast cancer cells, particularly ER-negative breast
cancer cells (94), and growth of tumors in ER-negative breast can-
cer in mice (95). In addition, several epidemiologic studies have
shown treatment with statins is associated with a reduced risk of
a number of cancers, including breast (96). However, other epi-
demiologic studies have produced conflicting results (97). One
meta-analysis of 16 breast cancer studies identified no preven-
tive efficacy of statins (98), while other studies demonstrated
significant reductions in breast cancer risk (99).
A number of Phase II prevention trials investigating the effects
of statins on breast tissue biomarkers are currently ongoing.
These studies have already demonstrated reduced proliferation
and increased apoptosis associated with short-term treatment
with statins (100, 101). Collectively, the results of epidemiologic,
preclinical, and clinical studies suggest that statins may prevent
breast cancer development and support the need for further inves-
tigation of their potential for the prevention of breast cancer,
particularly TNBC.
PARP INHIBITORS
Poly(ADP-ribose) polymerase is a BRCA1/2 mutation-dependent
DNA repair enzyme (102), and cells with loss of function BRCA1/2
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Table 4 | Select metformin breast cancer prevention studies (completed or with preliminary results).
Trial Study design Patient characteristics Results/primary endpoint(s)
TRIALSWITH PUBLISHED RESULTS
Hadad et al. (91) Metformin vs. non-metformin 55 Non-diabetic women with operable
invasive breast cancer
Reduction in Ki67 staining in metformin pilot
(5%) and metformin study (3.4%) groups
Bonanni et al. (92) Metformin vs. placebo 200 Non-diabetic women with
operable invasive breast cancer
Altered Ki67 staining overall (4.0%), in
HOMAa ≤2.8 (11.1%) and HOMAa>2.8
(−10.5%), and modified metformin effects in
luminal B tumors (as per HOMA index
Goodwin et al. (90),
Niraula et al. (93)
Metformin 39 Women under the age of 70 with
untreated, early-stage breast cancer
2.97% Reduction in Ki67 staining (±9.78%),
0.49% increase in TUNEL staining (±1.0%),
and patient toleration of drug
ONGOINGTRIALS (NO RESULTS PUBLISHEDTO DATE)
Goodwin et al.
Phase II NCT01310231
Metformin vs. placebo 78 Women with invasive breast cancer
diagnosed within the past year
Progression-free survival (PFS)
Patterson et al.
NCT01302379
Metformin vs. placebo in lifestyle
intervention and standard dietary
arms
340 Women with stage I–III breast
cancer diagnosed within the past
5 years
Breast cancer survival biomarker levels
Hershman et al.
Phase II NCT00930579
Metformin 35 Women with early invasive breast
cancer or DCIS
Measurement of effects on AMPK/mTOR
signaling and fasting serum insulin levels
Harris et al.
Phase III NCT01266486
Metformin 40 Participants with locally advanced
breast cancer
IHC analysis of effects on phosphorylation of
S6K, 4E-BP-1, and AMPK
Han et al.
Phase II NCT01589367
Metformin vs. placebo in
letrozole and no letrozole arms
208 Postmenopausal women with
stage I/II ER-positive breast cancer
Clinical response rate at 24 weeks and
comparison with RECIST 1.1 at baseline
Goodwin et al. (90)
Phase III NCIC-MA.32,
NCT01101438
Metformin vs. placebo 3,582 Non-diabetic participants with
stage I/II node-positive or high-risk
node-negative breast cancer
Invasive disease-free survival (IDFS)
DCIS, ductal carcinoma in situ; HR, hazard ratio; ER, estrogen receptor; HOMA, homeostasis model assessment.
aInsulin resistance: HOMA index>2.8, fasting glucose (mmol/L)× insulin (mU/L)/22.5.
mutations become selectively sensitive to the inhibition of PARP,
which impairs homologous recombination and results in the
induction of apoptosis (103). Several studies have shown that the
loss of function of BRCA makes the cells deficient in homologous
recombination DNA repair and makes these cells sensitive to PARP
inhibitors (104) (Figure 1).
Recent studies have demonstrated that many TNBCs are char-
acterized by shared sporadic and BRCA-mutated tumor character-
istics (BRCA-ness), which exhibit impaired homologous recombi-
nation (105). Through array comparative genomic hybridization
(aCGH) analyses, Lips et al. (105) have shown that a BRCA1-
like array pattern and methylation of the BRCA1 promoter are
apparent in 66–69 and 27–37% of TNBC tumors, respectively.
Clinical and preclinical data now suggests that PARP represents
an effective target for the treatment of TNBC. Initial results of a
Phase I clinical trial demonstrated that treatment with the PARP
inhibitor olaparib as a single agent or in combination with DNA-
damage-inducing chemotherapeutic agents is well-tolerated and
presents few side effects (106). In addition, a Phase II clinical trial
comparing the effects of chemotherapy alone vs. chemotherapy
and the PARP inhibitor iniparib in women with metastatic TNBC,
showed significant improvement of progression-free and overall
survival in patients receiving iniparib (107). These results have led
to a wave of additional clinical trials investigating the activity of
PARP inhibitors in breast cancer patients, and suggest a potential
utility and tolerability of PARP inhibitors for the prevention of
breast cancer.
Recent data from preclinical animal studies has now shown
that BRCA1 deficient mice treated with oral PARP inhibitors
exhibit significant delays in tumor development (Sporn and Liby,
unpublished results presented at the AACR Frontiers in Can-
cer Prevention Research Meeting, 2010). While this demonstrates
the potential usefulness of PARP inhibitors for the prevention of
ER-negative breast cancer, future results from clinical trials inves-
tigating PARP inhibitors for the prevention of breast cancer will
determine the applicability of preventive strategies targeting PARP
in women at high-risk of TNBC.
IGF, mTOR, AND S6K INHIBITORS
Recently, advances have been made in testing novel targeted drugs
in preclinical models, including mammalian target of rapamycin
(mTOR), PI3K, and IGF1R inhibitors (Figure 1). Results from
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studies of these inhibitors suggest that they may also prove to be
effective agents for the prevention of breast cancer.
The IGF1 pathway has been shown to be critical for mammary
gland development, and IGF1 inhibitors could prove useful for
prevention of both ER-positive and ER-negative breast cancers
(108, 109). Although many studies have demonstrated the effi-
cacy of IGF1R inhibition for the treatment of breast cancer, little
progress has been made in determining its effect for the preven-
tion of breast cancer (see Table 3). However, development of IGF
pathway inhibitors has been slowed by toxicity (hypoglycemia) of
drugs targeting this important pathway.
The PI3K/AKT/mTOR signaling pathway plays a critical role in
regulating angiogenesis, cell growth, and proliferation (110, 111).
mTOR is a serine-threonine kinase aberrantly and constitutively
activated in many breast tumors (112), and results in tumorige-
nesis, angiogenesis, estrogen independence, and drug resistance
(71, 113–115). Currently, several clinical trials are in progress
investigating the effect of mTOR inhibitors (including everolimus,
ridaforolimus, sirolimus, and temsirolimus) on HER2-positive
breast cancer (116). To date, results reported from these tri-
als have been contradictory. Preliminary results from Gepar-
Quinto trial (117, 118) did not show significant improvements in
pathologic response rates in women treated with both paclitaxel
and everolimus compared to paclitaxel treatment alone. Con-
versely, Baselga and Colleagues recently reported interim results
from the BOLERO-2 trial, which show improved progression-free
survival (HR 57%, 95% CI 0.35–0.54) associated with com-
bined exemestane-everolimus treatment vs. those receiving only
exemestane (119).
Several in vitro and in vivo preclinical studies have investi-
gated the potential mTOR inhibitors in the prevention of breast
cancer. Using a set of TNBC cell lines that represent the pro-
gression to breast cancer, it was determined that treatment with
rapamycin produces a larger effect on benign and pre-malignant
cells than on breast cancer cells (74). mTOR inhibitors have also
been investigated in a number of preclinical breast cancer pre-
vention studies using mouse models (see Table 3). deGraffenried
et al. have shown in vitro and in vivo mTOR inhibition and
restored tamoxifen sensitivity following treatment with the mTOR
inhibitor rapamycin (120). Recently, Hursting and Colleagues
reported that treatment with the mTOR inhibitor everolimus abol-
ishes the tumorigenic effects associated with obesity, improves
calorie restriction-mediated anticancer activity, and blocks mam-
mary tumor development and mTOR activation (121). These and
other positive results suggest mTOR inhibitors may prove to be
particularly useful cancer prevention agents in women at high-risk
of breast cancer.
Critical downstream kinases in the mTOR/S6K signaling path-
way are the ribosomal S6 kinases, with p70S6K (S6K1) functioning
as the main family member downstream of mTOR. p70S6K is acti-
vated by a variety of signals and induces cell growth, proliferation,
cell survival, and other oncogenic processes. p70S6K is frequently
amplified and overexpressed in cancer cells, and its hyperactivation
has been associated with the frequently mutated tumor suppres-
sor LKB1 (STK11) (122). siRNA or chemical inhibition (with
PF4708671) of S6K1 enhances cell death in glucose deprivation
conditions (123). Becker et al. recently reported that inhibition of
p70S6K inhibits IGF-induced ER activation, p70S6K binding, and
ER target gene activation (124). Another S6 kinase family mem-
ber, RSK (p90S6K), has been shown to regulate TNBC growth
and survival through the phosphorylation and activation of Y-box
binding protein-1 (YB-1) (125, 126). Although not tested in the
prevention of breast cancer yet, the recent findings on mTOR/S6K
pathway make it a promising target for the prevention of breast
cancer.
NATURAL PRODUCTS
Increased understanding of the correlation between a healthy diet
and reduced cancer incidence of a variety of cancer types, has led
many researchers to focus on natural products for the prevention
of cancer. According to the National Health and Nutrition Exam-
ination Survey (NHANES) over 49% of adults in the U.S. took a
dietary supplement between 2007 and 2010, of whom 32% took
dietary supplements containing an antioxidant (e.g., vitamins C
and E,β-carotene, resveratrol, flavonoids, or isoflavones) (127). Of
those adults taking supplements, NHANES data show that slightly
less than one quarter take them upon the recommendation of a
health care provider.
A recent meta-analysis of over 5,000 breast cancer cases,
reported an inverse association between green tea consumption
and breast cancer incidence (128). In 2012, our group reported
results from a Phase Ib clinical trial using green tea epigallocate-
chin gallate (EGCG) over a 6-month period, which was conducted
to determine the maximum tolerated dose (MTD) (129). Dur-
ing the treatment period no changes in breast tissue proliferation
were observed. Overall, the agent was well-tolerated, with toxicity
data establishing a 600-mg twice daily MTD for Poly E (EGCG).
A Phase II trial testing the cancer preventive effects of 1 year of
EGCG in postmenopausal women with high mammographic is
currently ongoing.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a non-
flavonoid polyphenol present in the skins of red grapes, mul-
berries, and other plants. Resveratrol has been reported to have
a wide range of health benefits through many different mech-
anisms of action. Recently, resveratrol has been implicated in
glucose metabolism, and has been shown to cause growth inhibi-
tion and apoptosis in cancer cells (130, 131). Although resveratrol
is well-known for its health benefits, its role as a cancer preven-
tive agent is not yet well-accepted. Further human studies need
to be performed to establish the appropriate dose and treatment
duration.
Many other vitamins and natural products are being tested as
cancer preventive agents, and specifically for breast cancer preven-
tion. Studies of these agents have been previously reviewed (132,
133). However, despite strong interest in using natural products
that have little known toxicities, none of these dietary agents have
yet been shown to have cancer preventive activity.
Currently, no FDA-approved drugs are available for tar-
geted breast cancer prevention in women at high-risk of
ER-negative breast cancer. However, a number of promising
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agents are being investigated in preclinical and clinical trials,
and encompass a wide range of targeted strategies, includ-
ing preventive therapy with drugs such as retinoids, COX-2
inhibitors, metformin, statins, PARP inhibitors, and signal trans-
duction (IGF, mTOR, S6K) inhibitors, as well as natural prod-
ucts, such as EGCG and resveratrol. In addition, vaccines and
behavioral strategies are being tested for breast cancer pre-
vention. The potential efficacy of many of these preventive
strategies for the prevention of ER-negative, and particularly
triple-negative, breast cancer will be determined in the near
future. The identification and development of multiple specific
agents targeting critical oncogenic pathways will be essential
for effective prevention of breast cancer in women at high risk
of TNBC.
CONCLUSION AND FUTURE PERSPECTIVE
Great progress has been made in the treatment and preven-
tion of ER-positive breast cancer. Most recently, several breast
cancer prevention trials targeting HER2 have demonstrated the
preventive efficacy of HER2-targeting drugs. However, the iden-
tification and develop of effective and safe targeted therapies
for the prevention of TNBC remains challenging. This difficulty
is exacerbated by the inherent heterogeneity of TNBC tumors,
and underlines the necessity for subtype-specific multi-targeted
approaches. Such combined strategies are critical for effective
treatment and prevention of women with or at high risk of TNBC
due to both the diverse signaling pathways driving the different
molecular subtypes, as well as the presence of cancer stem cells,
which are difficult to eradicate and are overrepresented in women
with TNBC.
Successful clinical breast cancer prevention trials hinge upon
the ability to identify high-risk individuals by breast cancer sub-
type, who therefore carry a high-potential benefit for the agent(s)
being tested in the study. However, educating women at risk for
breast cancer about the risks and benefits of the different can-
cer preventive drugs currently under investigation has been and
remains challenging. Although a large population of women qual-
ifies for these therapies, very few enroll in clinical breast cancer
prevention trials. As the majority of these drugs is well-tolerated
by breast cancer patients and are typically associated with only
minor side effects, the consent, and participation of healthy high-
risk women in clinical breast cancer prevention trials represents a
major hurdle to the development of novel therapeutic strategies.
Effective reduction of breast cancer incidence in the years to come,
particularly ER-negative and TNBC, ultimately depends upon the
identification of novel targets, the development of non-toxic drugs
that effectively interrupt the activity of those targets, and the deliv-
ery of these preventive therapies to women at high-risk of breast
cancers characterized by the targeted agents.
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